Mountain View Pharmaceuticals, Inc.
Mountain View Pharmaceuticals, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 2003, the company has established itself as a leader in developing innovative therapeutic solutions, particularly in the fields of oncology and neurology. With a strong operational presence across North America and Europe, Mountain View Pharmaceuticals focuses on delivering high-quality, patient-centric products that address unmet medical needs. The company’s core offerings include advanced drug formulations and cutting-edge delivery systems, which distinguish them in a competitive market. Notable achievements include successful collaborations with leading research institutions and a robust pipeline of clinical trials. Mountain View Pharmaceuticals continues to solidify its market position through a commitment to research and development, aiming to improve patient outcomes and enhance the quality of life for individuals facing serious health challenges.
DitchCarbon Score
How does Mountain View Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mountain View Pharmaceuticals, Inc.'s score of 7 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mountain View Pharmaceuticals, Inc.'s reported carbon emissions
In 2022, Mountain View Pharmaceuticals, Inc. reported total carbon emissions of approximately 700,900,000 kg CO2e across all scopes. This figure includes 22,500,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 40,500,000 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. The majority of their emissions, about 700,900,000 kg CO2e, fall under Scope 3, which includes all other indirect emissions that occur in the value chain. Comparatively, in 2021, the company emitted approximately 628,000,000 kg CO2e in Scope 3, alongside 23,800,000 kg CO2e in Scope 1 and 43,600,000 kg CO2e in Scope 2. In 2020, the emissions were slightly higher, with Scope 3 emissions at about 610,600,000 kg CO2e, Scope 1 at 25,200,000 kg CO2e, and Scope 2 at 45,800,000 kg CO2e. Despite these substantial emissions figures, Mountain View Pharmaceuticals, Inc. has not set specific reduction targets or initiatives, nor have they made any climate pledges. The absence of documented reduction initiatives or commitments suggests a need for further action in addressing their carbon footprint. The data reported is not cascaded from any parent organisation, indicating that these figures are solely from Mountain View Pharmaceuticals, Inc. itself.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 25,200,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 45,800,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 610,600,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mountain View Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
